한글목차

세계의 임상의사결정지원시스템(CDSS) 시장 규모는 예측 기간 동안 9.6%의 CAGR로 확대되어 2024년 22억 5,000만 달러에서 2030년에는 38억 9,000만 달러에 달할 것으로 예측됩니다.

이 시장의 성장은 주로 HIT 솔루션 채택을 촉진하기 위한 정부 규제 및 이니셔티브 시행, CDSS 지원 EHR 채택 확대, 이해관계자 간 협력 및 파트너십 확대, 약물 오남용 발생률 증가, 모바일 헬스 및 빅데이터 툴 시장 개척에 기인합니다. 그러나 CDSS 도입을 위한 높은 투자 요건, 불충분한 상호운용성, 데이터 보안에 대한 우려 증가 등은 예측 기간 동안 이 시장의 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.

구성요소별로 보면 임상의사결정지원시스템 시장은 서비스, 소프트웨어, 하드웨어로 나뉘며, 2024년 가장 빠르게 성장할 분야는 소프트웨어 분야입니다. 이는 주로 전자건강기록(EHR) 및 기타 임상 시스템과 원활하게 연동되는 통합 소프트웨어 솔루션의 채택이 증가하고 있기 때문입니다. 이러한 소프트웨어 플랫폼은 실시간 알림, 데이터 분석, 개인화된 추천과 같은 향상된 기능을 제공하여 임상 효율성과 의사결정을 개선하고, AI와 머신러닝의 발전은 CDSS 소프트웨어의 혁신을 더욱 촉진하여 보다 지능적이고 보다 지능적이고 확장 가능하며 사용자 친화적인 애플리케이션을 가능하게 하고 있습니다. 클라우드 기반 배포 및 구독 기반 모델로의 전환은 의료 서비스 제공자가 이러한 솔루션을 보다 쉽고 비용 효율적으로 이용할 수 있게함으로써 이 부문의 성장을 더욱 촉진하고 있습니다.

제공 형태에 따라 임상의사결정지원시스템 시장은 온프레미스형과 클라우드형으로 구분되며, 2024년에는 온프레미스형 CDSS 부문이 임상의사결정지원시스템 시장에서 가장 큰 점유율을 차지했습니다. 이는 특히 대형 병원 및 의료 기관에서 데이터 보안 및 관리에 대한 우려가 증가하고 있기 때문입니다. 온프레미스 솔루션을 통해 조직은 민감한 환자 데이터를 인프라 내에서 관리할 수 있어 정보 유출 위험을 줄이고 엄격한 데이터 보호 규정을 준수할 수 있습니다. 또한, 이러한 시스템은 사용자 정의가 가능하고, 기존 IT 인프라와 원활하게 통합되며, 소프트웨어 업그레이드를 유연하게 관리할 수 있기 때문에 의료 기관은 임상 업무에 지장을 주지 않고 새로운 기능을 테스트하고 직원을 교육할 수 있습니다.

2024년 세계 임상의사결정지원시스템 시장에서 북미가 가장 큰 점유율을 차지했습니다. 주요 산업 참여자의 존재, CDSS 도입을 지원하는 규제 당국의 지침, 미국과 캐나다의 약물 오류 증가가 이러한 추세에 기여하고 있습니다. 예측에 따르면, 아시아태평양은 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 이는 만성질환의 유병률 증가, 아시아 신흥국에 대한 다양한 시장 이해관계자들의 관심 증가 등의 요인에 기인합니다. 이러한 요인들은 아시아태평양의 임상의사결정지원시스템 시장의 성장을 촉진할 것으로 예상됩니다.

세계의 임상의사결정지원시스템 시장에 대해 조사했으며, 구성요소별, 제품별, 유형별, 모델별, 제공 형태별, 용도별, 인터랙티비티 수준별, 설정별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 소개
• 시장 역학
• 업계 동향
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
• 밸류체인 분석
• 생태계 분석
• 기술 분석
• 특허 분석
• 무역 분석
• 2025-2026년의 주요 회의와 이벤트
• 사례 연구 분석
• 관세와 규제 상황
• Porter's Five Forces 분석
• 비즈니스 모델
• 주요 이해관계자와 구입 기준
• 2025년 미국 관세의 영향

제6장 임상의사결정지원시스템 시장(구성요소별)

• 소개
• 서비스
• 소프트웨어
• 하드웨어

제7장 임상의사결정지원시스템 시장(제품별)

• 소개
• 통합 CDSS
• 독립형 CDSS

제8장 임상의사결정지원시스템 시장(유형별)

• 소개
• 치료 CDSS
• 진단 CDSS

제9장 임상의사결정지원시스템 시장(모델별)

• 소개
• 지식 기반 CDSS
• 비지식 기반 CDSS

제10장 임상의사결정지원시스템 시장(제공 형태별)

• 소개
• 온프레미스 CDSS
• 클라우드 기반 CDSS

제11장 임상의사결정지원시스템 시장(용도별)

• 소개
• 기존 CDSS
• 고도 CDSS

제12장 임상의사결정지원시스템 시장(상호작용 수준별)

• 소개
• 액티브 CDSS
• 패시브 CDSS

제13장 임상의사결정지원시스템 시장(설정별)

• 소개
• 입원 환자
• 외래 진료 환경

제14장 임상의사결정지원시스템 시장(지역별)

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타

제15장 경쟁 구도

• 소개
• 주요 진출 기업 전략, 2022-2025년
• 매출 분석, 2020-2024년
• 시장 점유율 분석, 2024년
• 기업 평가와 재무 지표
• 브랜드/제품 비교 분석
• 기업 평가 매트릭스 : 주요 진출 기업, 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
• 경쟁 시나리오

제16장 기업 개요

• 주요 진출 기업
  • EPIC SYSTEMS CORPORATION
  • WOLTERS KLUWER N.V.
  • ORACLE
  • MERATIVE
  • VERADIGM LLC
  • OPTUM, INC.(UNITEDHEALTH GROUP)
  • ATHENAHEALTH
  • ELSEVIER(DIVISION OF RELX GROUP)
  • ZYNX HEALTH, INC.
  • KONINKLIJKE PHILIPS N.V.
  • MEDICAL INFORMATION TECHNOLOGY, INC.
  • NEXTGEN HEALTHCARE, INC.
  • CUREMD HEALTHCARE
  • SIEMENS HEALTHINEERS AG
  • EBSCO INFORMATION SERVICES
  • GE HEALTHCARE
  • ECLINICALWORKS
  • THE MEDICAL ALGORITHMS COMPANY LIMITED
  • CARECLOUD, INC.
  • RAMPMEDICAL
• 기타 기업
  • MACUSOFT
  • HERA-MI
  • COHESIC INC.
  • MEDEA MIND
  • GLASS HEALTH
  • MEDECIPHER

제17장 부록

영문목차

The global clinical decision support systems (CDSS) market is projected to reach USD 3.89 billion by 2030 from USD 2.25 billion in 2024, at a CAGR of 9.6% during the forecast period. The growth of this market is primarily driven by implementing government regulations and initiatives to promote the adoption of HIT solutions, increasing adoption of CDSS-enabled EHRs, growing collaborations and partnerships between stakeholders, rising incidence of medication errors, and the development of mHealth and big data tools. However, high investment requirements for the implementation of CDSS and inadequate interoperability, coupled with rising data security concerns, are factors expected to restrain the growth of this market during the forecast period.

The software segment is expected to register the highest growth during the forecast period.

By component, the clinical decision support systems market is divided into services, software, and hardware. The software segment accounted for the fastest-growing segment of this market in 2024. It is driven primarily by the increasing adoption of integrated software solutions that seamlessly work with electronic health records (EHRs) and other clinical systems. These software platforms offer enhanced functionalities such as real-time alerts, data analytics, and personalized recommendations, which improve clinical efficiency and decision-making. Advancements in AI and machine learning are further driving innovation in CDSS software, enabling more intelligent, scalable, and user-friendly applications. The shift toward cloud-based deployments and subscription-based models is making these solutions more accessible and cost-effective for healthcare providers, further fueling growth in this segment.

The on-premise CDSS segment registered the largest share of the clinical decision support systems market in 2024.

By delivery mode, the clinical decision support systems market is divided into on-premise and cloud-based modes. In 2024, the on-premise CDSS segment is projected to hold the largest share of the clinical decision support systems market, primarily due to heightened concerns around data security and control, especially among large hospitals and healthcare institutions. On-premise solutions allow organizations to manage sensitive patient data within their infrastructure, reducing the risk of breaches and ensuring compliance with strict data protection regulations. These systems also offer greater customization, seamless integration with existing IT infrastructure, and flexibility in managing software upgrades, allowing institutions to test new features and train staff without disrupting clinical operations.

North America dominated the clinical decision support systems market in 2024.

North America accounted for the largest share of the global clinical decision support systems market in 2024. The existence of major industry participants, regulatory directives that support CDSS adoption, and the rise in medication errors in the US and Canada contribute to these trends. Forecasts indicate that the Asia Pacific region will witness the highest CAGR throughout the projected timeframe. This is due to factors such as the escalating prevalence of chronic illnesses and the growing attention of diverse market stakeholders toward emerging Asian nations. These factors are anticipated to propel the expansion of the clinical decision support systems market in the Asia Pacific region.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 45%, Tier 2: 35%, and Tier 3: 20%
• By Designation - Directors: 26%, Manager: 17%, and Others: 57%
• By Region - North America: 40%, Europe: 20%, Asia Pacific: 30%, Latin America: 6%, and Middle East & Africa: 4%

List of Companies Profiled in the Report

• Wolters Kluwer N.V. (Netherlands)
• Oracle (US)
• Merative (US)
• Change Healthcare (US)
• Veradigm Inc. (US)
• athenahealth (US)
• Epic Systems Corporation (US)
• Elsevier B.V. (Netherlands)
• Zynx Health (US)
• Koninklijke Philips N.V. (Netherlands)
• Medical Information Technology, Inc. (US)
• NextGen Healthcare, Inc. (US)
• CureMD Healthcare (US)
• Siemens Healthineers (Germany)
• EBSCO Information Services (US)
• GE HealthCare (US)
• eClinicalWorks (US)
• The Medical Algorithms Company (UK)
• RAMPmedical (Germany)
• Hera-MI (France)
• CareCloud, Inc. (US)
• VisualDx (US)
• Premier, Inc. (US)
• First Databank, Inc. (US)
• Strata Decision Technology (US).

Research Coverage

The report analyzes the clinical decision support systems market. It aims to estimate the market size and future growth potential of various market segments, based on component, delivery mode, product, model, interactivity level, application, setting, type, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges for market stakeholders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total clinical decision support systems market. The report forecasts the revenue of the market segments with respect to five major regions. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a higher share of the market. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (implementation of government regulations & initiatives to promote adoption of HCIT solutions, increasing adoption of CDSS-enabled EHRs, growing collaborations & partnerships between stakeholders, growing incidence of medication errors, development of big data and mHealth tools), restraints (data security concerns related to cloud-based CDSS, inadequate interoperability), opportunities (growth potential of emerging markets, social media integration and rising technological advancements), challenges (requirement of high investments for implementation of CDSS infrastructure, shortage of skilled IT professionals in healthcare industry)
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the clinical decision support systems market
• Market Development: Comprehensive information on the lucrative emerging markets, type of component, product, type, model, delivery mode, application, interactivity level, setting, and region
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the clinical decision support systems market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global clinical decision support systems market, such as Wolters Kluwer N.V. (Netherlands), Oracle (US), Merative (US), Change Healthcare (US), Veradigm Inc. (US), athenahealth (US), Epic Systems Corporation (US), Elsevier B.V. (Netherlands), Zynx Health (US), and Koninklijke Philips N.V. (Netherlands)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS SEGMENTATION AND REGIONS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 APPROACH 1: REVENUE SHARE ANALYSIS
  • 2.2.2 APPROACH 2: DEMAND-SIDE ANALYSIS
  • 2.2.3 APPROACH 3: BOTTOM-UP AND SEGMENTAL EXTRAPOLATION
• 2.3 GROWTH FORECAST MODEL
  • 2.3.1 PRIMARY INTERVIEWS
  • 2.3.2 TOP-DOWN APPROACH
  • 2.3.3 SEGMENT ASSESSMENT
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 SCOPE-RELATED LIMITATIONS
  • 2.6.2 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CLINICAL DECISION SUPPORT SYSTEMS MARKET OVERVIEW
• 4.2 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT AND COUNTRY
• 4.3 CLINICAL DECISION SUPPORT SYSTEMS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
• 4.4 CLINICAL DECISION SUPPORT SYSTEMS MARKET: REGIONAL MIX
• 4.5 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing government regulations for HCIT implementation
    • 5.2.1.2 Growing adoption of CDSS-enabled electronic health records
    • 5.2.1.3 Rising incidence of medication errors
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Data security concerns
    • 5.2.2.2 Inadequate interoperability for patient management solutions
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Development of big data and mHealth tools
    • 5.2.3.2 High growth potential in emerging economies
    • 5.2.3.3 Rising technological advancements
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High capital investments for CDSS infrastructure
    • 5.2.4.2 Shortage of skilled IT professionals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING APPLICATIONS OF AI
  • 5.3.2 INCREASING FOCUS ON MOBILE AND CLOUD-BASED SOLUTIONS
  • 5.3.3 ADOPTION OF HCIT SOLUTIONS
  • 5.3.4 GRADUAL SHIFT OF ACCOUNTABILITY FROM PAYERS TO PROVIDERS
  • 5.3.5 INCREASING DEMAND FOR VALUE-BASED HEALTHCARE
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE OF KEY PLAYER, BY PRODUCT
  • 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 TECHNOLOGY ANALYSIS
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT PUBLICATION TRENDS FOR CLINICAL DECISION SUPPORT SYSTEMS
  • 5.9.2 JURISDICTION ANALYSIS
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA FOR HS CODE 901890
  • 5.10.2 EXPORT DATA FOR HS CODE 901890
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 CASE STUDY ANALYSIS
  • 5.12.1 USE OF EVIDENCE-BASED NURSING KNOWLEDGE FOR PATIENT CARE
  • 5.12.2 USE OF KNOWLEDGE ANALYZER FOR WORKFLOW IMPROVEMENTS
  • 5.12.3 IMPROVED RESPONSE TIME AND PHYSICIAN EFFICIENCY IN HEALTHCARE FACILITIES WITH ELECTRONIC HEALTH RECORD
  • 5.12.4 ENHANCED EFFICIENCY AND VALUE-BASED CARE WITH AI-POWERED CDSS
• 5.13 TARIFF AND REGULATORY LANDSCAPE
  • 5.13.1 TARIFF FOR CDSS HARDWARE
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13.3 REGULATORY ANALYSIS
    • 5.13.3.1 North America
      • 5.13.3.1.1 Federal Food, Drug, and Cosmetic Act (FD&C Act)
      • 5.13.3.1.2 Health Insurance Portability and Accountability Act (HIPAA)
      • 5.13.3.1.3 Affordable Care Act, 2010
      • 5.13.3.1.4 Health Information Technology for Economic and Clinical Health Act, 2009 (HITECH)
      • 5.13.3.1.5 Consumer Privacy Protection Act, 2017
    • 5.13.3.2 Europe
      • 5.13.3.2.1 General Data Protection Regulation (GDPR)
      • 5.13.3.2.2 EU Cybersecurity Act
    • 5.13.3.3 Asia Pacific
      • 5.13.3.3.1 China's Cyber Security Law (CSL)
    • 5.13.3.4 Middle East & Africa
      • 5.13.3.4.1 Protection of Personal Information Act, South Africa
      • 5.13.3.4.2 Cloud Computing Regulatory Framework, South Africa
      • 5.13.3.4.3 Federal Law No. (2) of 2019, UAE
    • 5.13.3.5 Latin America
      • 5.13.3.5.1 Lei Geral de Protecao de Dados (General Data Protection Law), Brazil
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 BARGAINING POWER OF SUPPLIERS
  • 5.14.2 BARGAINING POWER OF BUYERS
  • 5.14.3 THREAT OF NEW ENTRANTS
  • 5.14.4 THREAT OF SUBSTITUTES
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 BUSINESS MODELS
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 IMPACT OF 2025 US TARIFF
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 IMPACT ON COUNTRY/REGION
    • 5.17.4.1 US
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
  • 5.17.5 IMPACT ON END-USE INDUSTRIES
    • 5.17.5.1 Inpatient settings
    • 5.17.5.2 Ambulatory care settings
  • 5.17.6 CONCLUSION

6 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT

• 6.1 INTRODUCTION
• 6.2 SERVICES
  • 6.2.1 INCREASING RELIANCE OF HEALTHCARE IT INDUSTRY ON SERVICES TO DRIVE MARKET
• 6.3 SOFTWARE
  • 6.3.1 FREQUENT NEED FOR UPGRADES AND IMPROVEMENTS IN SOFTWARE APPLICATIONS TO PROPEL MARKET
• 6.4 HARDWARE
  • 6.4.1 NEED TO OPTIMIZE SOFTWARE TO AUGMENT GROWTH

7 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 INTEGRATED CDSS
  • 7.2.1 GROWING FOCUS ON QUALITY HEALTHCARE AND REDUCING MEDICATION ERRORS TO BOOST MARKET
• 7.3 STANDALONE CDSS
  • 7.3.1 LACK OF REPORTING AND ELECTRONIC HEALTH RECORDS TO LIMIT GROWTH

8 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 THERAPEUTIC CDSS
  • 8.2.1 SEAMLESS INTEGRATION INTO CLINICAL WORKFLOWS TO PROMOTE GROWTH
• 8.3 DIAGNOSTIC CDSS
  • 8.3.1 RISING USE OF ALGORITHMS FOR EFFECTIVE REAL-TIME DIAGNOSIS TO SUPPORT GROWTH

9 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL

• 9.1 INTRODUCTION
• 9.2 KNOWLEDGE-BASED CDSS
  • 9.2.1 INCREASING FOCUS ON PRECISION COURSE OF TREATMENT TO AID GROWTH
• 9.3 NON-KNOWLEDGE-BASED CDSS
  • 9.3.1 GROWING ADOPTION OF ARTIFICIAL INTELLIGENCE TO DRIVE MARKET

10 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE

• 10.1 INTRODUCTION
• 10.2 ON-PREMISE CDSS
  • 10.2.1 LOWER RISK OF DATA BREACH AND ABILITY TO CHOOSE MULTIPLE VENDORS TO SUSTAIN GROWTH
• 10.3 CLOUD-BASED CDSS
  • 10.3.1 FLEXIBLE AND SCALABLE FEATURES TO CONTRIBUTE TO GROWTH

11 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 CONVENTIONAL CDSS
  • 11.2.1 ABILITY TO PROVIDE DIAGNOSTIC ASSISTANCE AND PRESCRIPTION DECISION SUPPORT TO DRIVE MARKET
• 11.3 ADVANCED CDSS
  • 11.3.1 REAL-TIME EVIDENCE AND PROTOCOL VALIDATION BENEFITS TO STIMULATE GROWTH

12 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL

• 12.1 INTRODUCTION
• 12.2 ACTIVE CDSS
  • 12.2.1 ABILITY TO ENABLE OPTIMAL DECISION-MAKING WITH MINIMAL ERRORS TO ACCELERATE GROWTH
• 12.3 PASSIVE CDSS
  • 12.3.1 MINIMAL DISRUPTION TO WORKFLOWS TO ENCOURAGE GROWTH

13 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING

• 13.1 INTRODUCTION
• 13.2 INPATIENT SETTINGS
  • 13.2.1 GROWING FOCUS ON IMPROVING HEALTHCARE OPERATIONS IN HOSPITALS TO PROPEL MARKET
• 13.3 AMBULATORY CARE SETTINGS
  • 13.3.1 RISING NEED TO CURB HEALTHCARE COSTS TO FACILITATE GROWTH

14 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 14.2.2 US
    • 14.2.2.1 Growing focus on value-based care to drive market
  • 14.2.3 CANADA
    • 14.2.3.1 Increasing regulations regarding safety & quality care to speed up growth
• 14.3 EUROPE
  • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 14.3.2 GERMANY
    • 14.3.2.1 Favorable government support for adoption of electronic medical records to propel market
  • 14.3.3 UK
    • 14.3.3.1 Rising establishment of healthcare facilities to accelerate growth
  • 14.3.4 FRANCE
    • 14.3.4.1 Growing focus on improving healthcare coordination to drive market
  • 14.3.5 ITALY
    • 14.3.5.1 Rising need for evidence-based CDSS to drive market
  • 14.3.6 SPAIN
    • 14.3.6.1 Growing focus on improving patient outcomes to boost market
  • 14.3.7 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 14.4.2 JAPAN
    • 14.4.2.1 Rising need to digitize patient records to bolster growth
  • 14.4.3 CHINA
    • 14.4.3.1 Favorable government support to drive market
  • 14.4.4 INDIA
    • 14.4.4.1 Rising adoption of telemedicine to favor growth
  • 14.4.5 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 14.5.2 BRAZIL
    • 14.5.2.1 Rising demand to digitize patient records to amplify growth
  • 14.5.3 MEXICO
    • 14.5.3.1 Established healthcare reforms to contribute to growth
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 14.6.2 GCC COUNTRIES
    • 14.6.2.1 Growing investments in healthcare infrastructure to propel market
  • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES, 2022-2025
• 15.3 REVENUE ANALYSIS, 2020-2024
• 15.4 MARKET SHARE ANALYSIS, 2024
• 15.5 COMPANY VALUATION AND FINANCIAL METRICS
• 15.6 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 15.7.1 STARS
  • 15.7.2 EMERGING LEADERS
  • 15.7.3 PERVASIVE PLAYERS
  • 15.7.4 PARTICIPANTS
  • 15.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 15.7.5.1 Company footprint
    • 15.7.5.2 Region footprint
    • 15.7.5.3 Application & product footprint
    • 15.7.5.4 Type footprint
• 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 15.8.1 PROGRESSIVE COMPANIES
  • 15.8.2 RESPONSIVE COMPANIES
  • 15.8.3 DYNAMIC COMPANIES
  • 15.8.4 STARTING BLOCKS
  • 15.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 15.8.5.1 Detailed list of key startups/SMEs
    • 15.8.5.2 Competitive benchmarking of key startups/SMEs
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS
  • 15.9.2 DEALS
  • 15.9.3 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 EPIC SYSTEMS CORPORATION
    • 16.1.1.1 Business overview
    • 16.1.1.2 Solutions offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Solution launches/enhancements/approvals
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Other developments
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses and competitive threats
  • 16.1.2 WOLTERS KLUWER N.V.
    • 16.1.2.1 Business overview
    • 16.1.2.2 Solutions offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Solution launches/enhancements/approvals
      • 16.1.2.3.2 Deals
      • 16.1.2.3.3 Other developments
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses and competitive threats
  • 16.1.3 ORACLE
    • 16.1.3.1 Business overview
    • 16.1.3.2 Solutions offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Solution launches/enhancements/approvals
      • 16.1.3.3.2 Deals
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Key strengths
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses and competitive threats
  • 16.1.4 MERATIVE
    • 16.1.4.1 Business overview
    • 16.1.4.2 Solutions offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Solution launches/enhancements/approvals
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses and competitive threats
  • 16.1.5 VERADIGM LLC
    • 16.1.5.1 Business overview
    • 16.1.5.2 Solutions offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Solution launches/enhancements/approvals
      • 16.1.5.3.2 Deals
      • 16.1.5.3.3 Other developments
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Key strengths
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses and competitive threats
  • 16.1.6 OPTUM, INC. (UNITEDHEALTH GROUP)
    • 16.1.6.1 Business overview
    • 16.1.6.2 Solutions offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Solution launches/enhancements/approvals
      • 16.1.6.3.2 Deals
  • 16.1.7 ATHENAHEALTH
    • 16.1.7.1 Business overview
    • 16.1.7.2 Solutions offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Solution launches/enhancements/approvals
      • 16.1.7.3.2 Deals
  • 16.1.8 ELSEVIER (DIVISION OF RELX GROUP)
    • 16.1.8.1 Business overview
    • 16.1.8.2 Solutions offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Solution launches/enhancements/approvals
      • 16.1.8.3.2 Deals
  • 16.1.9 ZYNX HEALTH, INC.
    • 16.1.9.1 Business overview
    • 16.1.9.2 Solutions offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Solution launches/enhancements/approvals
      • 16.1.9.3.2 Deals
      • 16.1.9.3.3 Other developments
  • 16.1.10 KONINKLIJKE PHILIPS N.V.
    • 16.1.10.1 Business overview
    • 16.1.10.2 Solutions offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Product launches/enhancements/approvals
  • 16.1.11 MEDICAL INFORMATION TECHNOLOGY, INC.
    • 16.1.11.1 Business overview
    • 16.1.11.2 Solutions offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Product launches/enhancements/approvals
      • 16.1.11.3.2 Deals
      • 16.1.11.3.3 Other developments
  • 16.1.12 NEXTGEN HEALTHCARE, INC.
    • 16.1.12.1 Business overview
    • 16.1.12.2 Solutions offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Solution launches/enhancements/approvals
      • 16.1.12.3.2 Deals
      • 16.1.12.3.3 Other developments
  • 16.1.13 CUREMD HEALTHCARE
    • 16.1.13.1 Business overview
    • 16.1.13.2 Solutions offered
      • 16.1.13.2.1 Deals
      • 16.1.13.2.2 Other developments
  • 16.1.14 SIEMENS HEALTHINEERS AG
    • 16.1.14.1 Business overview
    • 16.1.14.2 Solutions offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Deals
  • 16.1.15 EBSCO INFORMATION SERVICES
    • 16.1.15.1 Business overview
    • 16.1.15.2 Solutions offered
    • 16.1.15.3 Recent developments
      • 16.1.15.3.1 Solution launches/enhancements/approvals
      • 16.1.15.3.2 Deals
      • 16.1.15.3.3 Other developments
  • 16.1.16 GE HEALTHCARE
    • 16.1.16.1 Business overview
    • 16.1.16.2 Solutions offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Solution launches/enhancements/approvals
      • 16.1.16.3.2 Deals
      • 16.1.16.3.3 Other developments
  • 16.1.17 ECLINICALWORKS
    • 16.1.17.1 Business overview
    • 16.1.17.2 Solutions offered
    • 16.1.17.3 Recent developments
      • 16.1.17.3.1 Solution launches/enhancements/approvals
    • 16.1.17.4 Recent developments
      • 16.1.17.4.1 Deals
  • 16.1.18 THE MEDICAL ALGORITHMS COMPANY LIMITED
    • 16.1.18.1 Business overview
    • 16.1.18.2 Solutions offered
  • 16.1.19 CARECLOUD, INC.
    • 16.1.19.1 Business overview
    • 16.1.19.2 Solutions offered
    • 16.1.19.3 Recent developments
      • 16.1.19.3.1 Solution launches/enhancements/approvals
      • 16.1.19.3.2 Deals
      • 16.1.19.3.3 Expansions
  • 16.1.20 RAMPMEDICAL
    • 16.1.20.1 Business overview
    • 16.1.20.2 Solutions offered
• 16.2 OTHER PLAYERS
  • 16.2.1 MACUSOFT
  • 16.2.2 HERA-MI
  • 16.2.3 COHESIC INC.
  • 16.2.4 MEDEA MIND
  • 16.2.5 GLASS HEALTH
  • 16.2.6 MEDECIPHER

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS